These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27367495)

  • 21. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
    Lip GY; Pan X; Kamble S; Kawabata H; Mardekian J; Masseria C; Bruno A; Phatak H
    Int J Clin Pract; 2016 Sep; 70(9):752-63. PubMed ID: 27550177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of intraocular hemorrhage with new oral anticoagulants.
    Talany G; Guo M; Etminan M
    Eye (Lond); 2017 Apr; 31(4):628-631. PubMed ID: 28009346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticoagulant-associated adverse drug reactions in 2013-15.
    Eek AK; Strøm BO; Bakkehøi G; Stenberg-Nilsen H
    Tidsskr Nor Laegeforen; 2018 Aug; 138(12):. PubMed ID: 30132616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the efficacy and safety of new oral anticoagulant drugs in the secondary stroke prevention in patients with AF: single center experience based on 311 patients.
    Lasek-Bal A; Urbanek T; Gierek D
    Int Angiol; 2015 Dec; 34(6):552-61. PubMed ID: 25410296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program.
    Perlman A; Horwitz E; Hirsh-Raccah B; Aldouby-Bier G; Fisher Negev T; Hochberg-Klein S; Kalish Y; Muszkat M
    Isr J Health Policy Res; 2019 Feb; 8(1):19. PubMed ID: 30709417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct oral anticoagulants (DOACs).
    Vazquez S; Rondina MT
    Vasc Med; 2015 Dec; 20(6):575-7. PubMed ID: 26285587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Gastrointestinal bleeding during treatment with non­vitamin K antagonist oral anticoagulants (NOACs) may be caused by malignant lesions].
    Haeggström A; Risberg D; Al-Kahlili F; Gilstring Å; Tullberg U; Wallén H
    Lakartidningen; 2016 Nov; 113():. PubMed ID: 27824386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of radial coronary angiography with uninterrupted direct-acting oral anticoagulant treatment.
    Kemaloğlu Öz T; Gürol T; Sarıgül NU; Aslan U; Kobegenova M; Aydın A; Soylu Ö; Dağdeviren B
    Turk Kardiyol Dern Ars; 2019 Jan; 47(1):4-9. PubMed ID: 30628896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation of adverse drug reactions associated with direct oral anticoagulants recorded in the Italian Pharmacovigilance Network database using a specifically developed risk index].
    Uguccioni M; Terranova A; Di Lullo L
    G Ital Cardiol (Rome); 2018 Oct; 19(10 Suppl 1):3S-11S. PubMed ID: 30281039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gastrointestinal bleeding risk of non-vitamin K oral anticoagulants is similar to warfarin - a Japanese retrospective cohort study
.
    Shirai T; Yamamoto T; Kawasugi K; Kuyama Y; Kita H
    Int J Clin Pharmacol Ther; 2016 Nov; 54(11):841-846. PubMed ID: 27569738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends and Characteristics of Emergency Department Patients Prescribed Novel Oral Anticoagulants.
    Ganetsky M
    J Emerg Med; 2015 Nov; 49(5):693-7. PubMed ID: 26149803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
    Malec K; Góralczyk T; Undas A
    Thromb Res; 2017 Apr; 152():93-97. PubMed ID: 27989533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous thrombolysis for stroke in patients taking non-VKA oral anticoagulants: an update.
    Cappellari M; Bovi P
    Thromb Haemost; 2015 Aug; 114(2):440-4. PubMed ID: 25809649
    [No Abstract]   [Full Text] [Related]  

  • 40. Major bleeding complications in patients treated with direct oral anticoagulants: One-year observational study in a Paris Hospital.
    Deville L; Konan M; Hij A; Goldwirt L; Peyrony O; Fieux F; Faure P; Madelaine I; Villiers S; Farge-Bancel D; Frère C
    Curr Res Transl Med; 2016; 64(3):129-133. PubMed ID: 27765272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.